Israeli-founded AI biotech Immunai expands AstraZeneca cancer collaboration
The expanded agreement extends and broadens the companies’ multi-year collaboration in oncology through 2027, according to the statement.
Story
JPost.com - Business & Innovation · Israel
Join the conversation
Discuss the story with the TraceFeed community.
No comments yet. Be the first to add a perspective.